US3976544A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Water-soluble immunological adjuvants, in particular for vaccines, obtained from mycobacteria and related microorganisms and process for their extraction
Assignee: Bpifrance Financement SA
•
Filing: 1973-06-19
•
Granted: 1976-08-24
•
Expires: 1993-06-19
Abstract
Abstract The invention pertains to a water-soluble immunological adjuvant, especially for vaccines. It is obtained by enzymatic treatment of mycobacteria or Nocardia whole cells in aqueous medium and by a recovery from said aqueous medium.
Inventors
- 👤 Arlette Adam
- 👤 Frank Berger
- 👤 Louis Chedid
- 👤 Edgar Lederer
- 👤 Jean-Francois Petit
- 👤 Rita Ciorbaru
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 14:17
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/195; C07K14/35; A; A61; A61K; A61K39/00; A61K39/39; A61K2039/555; A61K2039/55588; A61K2039/55594; A61K38/00; Y; Y10; Y10S; Y10S435/00; Y10S435/803; Y10S435/8215; Y10S435/822; Y10S435/863; Y10S435/866
Claims Analysis
Total Claims: 16
Claim 1
Independent Claim
70 words
In the process for preparing a water-soluble immunological non-specific adjuvant which comprises treating an aqueous suspension of solvent-extracted delipidated whole cells of pathogenic and non-pathogenic Mycobacteria or Nocardia micro-organisms with a muramidase to free the immunological non-specific adjuvant, separating the solid fraction from the mixture, recovering the aqueous portion containing amino-acids other than those of the peptidoglycan and the immunological non-specific adjuvant, the adjuvant having reduced sensitizing action to tuberculine.
Claim 2
Dependent Claim
70 words
In the process for preparing a water-soluble immunological non-specific adjuvant which comprises treating an aqueous suspension of solvent-extracted delipidated whole cells of pathogenic and non-pathogenic Mycobacteria or Nocardia micro-organisms with a muramidase to free the immunological non-specific adjuvant, separating the solid fraction from the mixture, recovering the aqueous portion containing amino-acids other than those of the peptidoglycan and the immunological non-specific adjuvant, the adjuvant having reduced sensitizing action to tuberculine.
Claim 3
Dependent Claim
10 words
The process of claim 1 wherein the muramidase is lysozyme.
Claim 4
Dependent Claim
24 words
The process of claim 1 which comprises the additional step of lyophilizing the aqueous fraction containing the immunological adjuvant, thereby obtaining a water-soluble product.
Claim 5
Dependent Claim
21 words
The process of claim 3 which comprises the additional step of taking up the dry lyophilized extract in an aqueous solution.
Claim 6
Dependent Claim
36 words
The process of claim 1 which comprises, for further purification, the additional step of incubating the aqueous medium of the immunological adjuvant with a proteolytic enzyme, whereby amino-acids are removed, and separating the more purified adjuvant.
Claim 7
Dependent Claim
10 words
The process of claim 5 wherein the enzyme is trypsin.
Claim 8
Dependent Claim
21 words
The process of claim 5 in which the aqueous medium is buffered at a pH from about 7.5 to about 8.2
Claim 9
Dependent Claim
37 words
The process of claim 1 which comprises the additional step of filtering the aqueous solution of the immunological adjuvant on a molecular sieve and recovering the filtrate containing the more purified aqueous solution containing the immunological adjuvant.
Claim 10
Dependent Claim
14 words
The process of claim 8 wherein the molecular sieve is of a polydextran column.
Claim 11
Dependent Claim
48 words
The process of claim 9 which comprises eluting with acetic acid several fractions from the column and collecting either the first or second fraction or the second and third fraction of the aqueous filtrate corresponding to the corresponding elution peak, said fractions containing the more purified immunological adjuvant.
Claim 12
Dependent Claim
29 words
The process of claim 10 in which the first or second fraction of the aqueous filtrate corresponding to the first or second elution peak of the filtrate, is recovered.
Claim 13
Dependent Claim
29 words
The process of claim 10 in which the second or third fraction of the aqueous filtrate corresponding to the second or third elution peak of the filtrate, is recovered.
Claim 14
Dependent Claim
19 words
The process of claim 1 in which the immunological non-specific adjuvant contains neutral sugars, amino sugars and amino acids.
Claim 15
Dependent Claim
95 words
In the process for preparing a water-soluble immunological non-specific adjuvant which comprises treating an aqueous suspension of solvent-extracted delipidated whole cells of pathogenic and non-pathogenic Mycobacteria or Nocardia micro-organisms with a muramidase to free the immunological non-specific adjuvant, separating the solid fraction from the mixture, incubating the aqueous medium of the immunological adjuvant with a proteolytic enzyme, thereby removing amino acids, filtering the aqueous solution of the immunological adjuvant on a molecular sieve and recovering the filtrate containing the more purified aqueous solution containing the immunological adjuvant, the adjuvant having reduced sensitizing action to tuberculine.
Claim 16
Dependent Claim
95 words
In the process for preparing a water-soluble immunological non-specific adjuvant which comprises treating an aqueous suspension of solvent-extracted delipidated whole cells of pathogenic and non-pathogenic Mycobacteria or Nocardia micro-organisms with a muramidase to free the immunological non-specific adjuvant, separating the solid fraction from the mixture, incubating the aqueous medium of the immunological adjuvant with a proteolytic enzyme, thereby removing amino acids, filtering the aqueous solution of the immunological adjuvant on a molecular sieve and recovering the filtrate containing the more purified aqueous solution containing the immunological adjuvant, the adjuvant having reduced sensitizing action to tuberculine.
References Cited (Backward Citations)
US3529057A
Cited
US3876779A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1979-08-24 | 1980-02-23 | 1980-08-24 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1983-08-24 | 1984-02-23 | 1984-08-24 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1987-08-24 | 1988-02-23 | 1988-08-24 | $7700.00 | Window Closed / Lapsed |